Review



tma bl2081  (Biomax Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Biomax Inc tma bl2081
    EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
    Tma Bl2081, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tma+bl2081/tissue+array+blocks+bl+806/pmc06375935-61-10-7
    Average 90 stars, based on 1 article reviews
    tma bl2081 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)"

    Article Title: Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)

    Journal: Scientific Reports

    doi: 10.1038/s41598-019-38575-x

    EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
    Figure Legend Snippet: EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

    Techniques Used: Expressing, Staining



    Similar Products

    tma bl2081  (Biomax Inc)
    90
    Biomax Inc tma bl2081
    EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
    Tma Bl2081, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tma+bl2081/tissue+array+blocks+bl+806/pmc06375935-61-10-7
    Average 90 stars, based on 1 article reviews
    tma bl2081 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

    Journal: Scientific Reports

    Article Title: Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)

    doi: 10.1038/s41598-019-38575-x

    Figure Lengend Snippet: EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

    Article Snippet: Two commercially available TMAs were purchased from Biomax (Rockville, MD): BL2081 and BL806.

    Techniques: Expressing, Staining